Rasmi G. Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rasmi G. Nair has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Celette Sugg Skinner
Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX
19 shared publications - Ethan A. Halm
Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901
19 shared publications - Caitlin C. Murphy
Section of Hematology and Oncology,Department of Pediatrics, The University of Chicago, Chicago, USA
18 shared publications - Po-Hong Liu
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
18 shared publications - Beverly B. Green
Kaiser Permanente Washington Health Research Institute, Seattle, Washington
17 shared publications - Cynthia Ortiz
Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas
17 shared publications
Latest Publications
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (5) , 683-693
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas
PURPOSE: To study the influence of the Affordable Care Act (ACA) policy and its Medicaid expansion on insurance status and survival in patients with HIV with aggressive lymphoma. METHODS: We used the National Cancer Database, a hospital-based national registry, to identify adults age 18-64 years with HIV-associated aggressive B-cell non-Hodgkin lymphomas (HIV-a-B-NHLs), diagnosed during 2007 to 2016. Survival analysis was performed on a subset of patients with HIV-a-B-NHL for whom location data were available who resided in Medicaid expansion–adopted and nonadopted states. Using a quasi-experimental difference-in-difference model, the difference in adjusted 2-year survival rates obtained with a flexible parametric Weibull model was compared for states that adopted the Medicaid expansion of ACA against those that did not adopt the expansion. RESULTS: We identified 8,231 patients with HIV-a-B-NHL and 50,650 non-HIV patients with a-B-NHL. We found that a lower proportion of individuals were uninsured at diagnosis in the expansion states compared with nonexpansion states. We also found that the ACA policy adoption led to a reduction in the proportion of uninsured individuals with HIV-a-B-NHL in expansion states of 34.9%, compared with 15.9% in non–expansion-adopted states. There was a statistically significant improvement in the 2-year survival rate among patients with HIV-a-B-NHL in the expansion compared with nonexpansion states with the adoption of ACA (7.17% v 1.58%, P = .02). CONCLUSION: Using a novel quasi-experimental model, we found that the ACA policy corresponded with a greater survival improvement in patients with HIV-a-B-NHL within Medicaid expansion–adopted states compared with nonexpansion states. We believe that this evidence should be taken into consideration in future policy making.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (5) , 683-693
Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas
PURPOSE: To study the influence of the Affordable Care Act (ACA) policy and its Medicaid expansion on insurance status and survival in patients with HIV with aggressive lymphoma. METHODS: We used the National Cancer Database, a hospital-based national registry, to identify adults age 18-64 years with HIV-associated aggressive B-cell non-Hodgkin lymphomas (HIV-a-B-NHLs), diagnosed during 2007 to 2016. Survival analysis was performed on a subset of patients with HIV-a-B-NHL for whom location data were available who resided in Medicaid expansion–adopted and nonadopted states. Using a quasi-experimental difference-in-difference model, the difference in adjusted 2-year survival rates obtained with a flexible parametric Weibull model was compared for states that adopted the Medicaid expansion of ACA against those that did not adopt the expansion. RESULTS: We identified 8,231 patients with HIV-a-B-NHL and 50,650 non-HIV patients with a-B-NHL. We found that a lower proportion of individuals were uninsured at diagnosis in the expansion states compared with nonexpansion states. We also found that the ACA policy adoption led to a reduction in the proportion of uninsured individuals with HIV-a-B-NHL in expansion states of 34.9%, compared with 15.9% in non–expansion-adopted states. There was a statistically significant improvement in the 2-year survival rate among patients with HIV-a-B-NHL in the expansion compared with nonexpansion states with the adoption of ACA (7.17% v 1.58%, P = .02). CONCLUSION: Using a novel quasi-experimental model, we found that the ACA policy corresponded with a greater survival improvement in patients with HIV-a-B-NHL within Medicaid expansion–adopted states compared with nonexpansion states. We believe that this evidence should be taken into consideration in future policy making.
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure depicts reasons for unsatisfactory FIT based on type of FIT
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure depicts reasons for unsatisfactory FIT based on type of FIT
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows results of sensitivity analysis - Factors associated with subsequent testing within 9 months among patients with unsatisfactory fecal immunochemical test
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows results of sensitivity analysis - Factors associated with subsequent testing within 9 months among patients with unsatisfactory fecal immunochemical test
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure depicts CRC screening programs at Parkland over the study period
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure depicts CRC screening programs at Parkland over the study period
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table tabulates reasons for unsatisfactory FIT based on free-text responses entered by laboratory technician in EHR
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table tabulates reasons for unsatisfactory FIT based on free-text responses entered by laboratory technician in EHR
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows subsequent testing patterns within 15 months after an unsatisfactory FIT
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows subsequent testing patterns within 15 months after an unsatisfactory FIT
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows subsequent testing patterns within 15 months after an unsatisfactory FIT
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows subsequent testing patterns within 15 months after an unsatisfactory FIT
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure depicts CRC screening programs at Parkland over the study period
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure depicts CRC screening programs at Parkland over the study period
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure shows prevalence of unsatisfactory FIT over the study period
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This figure shows prevalence of unsatisfactory FIT over the study period
- Open Access
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows results of sensitivity analysis - Factors associated with subsequent testing within 9 months among patients with unsatisfactory fecal immunochemical test
- 6 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing
This table shows results of sensitivity analysis - Factors associated with subsequent testing within 9 months among patients with unsatisfactory fecal immunochemical test